<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Eptifibatide: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Eptifibatide: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Eptifibatide: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11943" href="/d/html/11943.html" rel="external">see "Eptifibatide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F166052"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Integrilin [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866758"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Integrilin [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F166082"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiplatelet Agent, Glycoprotein IIb/IIIa Inhibitor</li></ul></div>
<div class="block doa drugH1Div" id="F166055"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c422ce2-49d1-404f-9c62-15c216a263dd">Acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Routine antithrombotic therapy for patients undergoing percutaneous coronary intervention (PCI) includes oral antiplatelet therapy (eg, aspirin plus a P2Y12 inhibitor) and an IV anticoagulant (eg, heparin or bivalirudin). A glycoprotein IIb/IIIa inhibitor is not routinely used due to limited benefit on ischemic outcomes and more bleeding complications. However, use may be considered in high-risk patients (eg, significant thrombus burden) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-17124018','lexi-content-ref-18499566']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-17124018','lexi-content-ref-18499566'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Non-ST elevation acute coronary syndromes: IV:</b> Bolus of 180 mcg/kg (maximum: 22.6 mg) beginning after diagnostic coronary angiography, just before PCI, followed by a continuous infusion of 2 mcg/kg/minute (maximum: 15 mg/hour); a second bolus of 180 mcg/kg (maximum: 22.6 mg) should be administered 10 minutes after the first bolus; continue infusion for up to 18 to 24 hours after PCI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950','lexi-content-ref-19332455','lexi-content-ref-17299194']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950','lexi-content-ref-19332455','lexi-content-ref-17299194'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>ST elevation myocardial infarction (off-label use): IV:</b> Bolus of 180 mcg/kg (maximum: 22.6 mg) beginning after diagnostic coronary angiography, just before PCI, followed by a continuous infusion of 2 mcg/kg/minute (maximum: 15 mg/hour); a second bolus of 180 mcg/kg (maximum: 22.6 mg) should be administered 10 minutes after the first bolus; continue infusion for up to 18 to 24 hours after PCI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f87074c1-a208-4876-b6cc-70b7276a67a2">Percutaneous coronary intervention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Percutaneous</b>
<b> coronary</b>
<b> intervention:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Routine antithrombotic therapy for patients undergoing percutaneous coronary intervention (PCI) includes oral antiplatelet therapy (eg, aspirin plus a P2Y12 inhibitor) and an IV anticoagulant (eg, heparin or bivalirudin). A glycoprotein IIb/IIIa inhibitor is not routinely used due to limited benefit on ischemic outcomes and more bleeding complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Bolus of 180 mcg/kg (maximum bolus: 22.6 mg) beginning after diagnostic coronary angiography, just before PCI, followed by a continuous infusion of 2 mcg/kg/minute (maximum: 15 mg/hour); a second bolus of 180 mcg/kg (maximum: 22.6 mg) should be administered 10 minutes after the first bolus; may administer continuous infusion for up to 18 to 24 hours after PCI or until hospital discharge, whichever comes first; alternatively, some administer the continuous infusion for only &lt;2 hours after PCI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19264239','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19264239','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> If coronary artery bypass graft surgery is performed, discontinue eptifibatide ≥4 hours before surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34895950']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34895950'])">Ref</a></span>); pharmacokinetic studies indicate that platelet function is restored ~4 to 8 hours after discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11468200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11468200'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991871"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> The Cockcroft-Gault equation using actual body weight should be used to estimate renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl ≥50 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCl &lt;50 mL/minute: <b>IV:</b> Bolus of 180 mcg/kg (maximum: 22.6 mg) beginning after diagnostic coronary angiography, just before percutaneous coronary intervention (PCI), followed by a continuous infusion of 1 mcg/kg/minute (maximum: 7.5 mg/hour); a second bolus of 180 mcg/kg (maximum: 22.6 mg) should be administered 10 minutes after the first bolus; continue infusion for up to 18 to 24 hours after PCI.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease (ie, dialysis dependent): Use is contraindicated.</p>
<p style="text-indent:-2em;margin-left:2em;">Hemodialysis: Dialyzable: Yes; ~73 to 83% removed after 1 hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26714677']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26714677'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50989181"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F166056"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing. No dosing adjustment for the elderly appears to be necessary; adjust carefully to renal function.</p></div>
<div class="block adr drugH1Div" id="F166025"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined. Bleeding is the major drug-related adverse effect. Access site is often primary source of bleeding complications. Incidence of bleeding is also related to heparin intensity. Patients weighing &lt;70 kg may have an increased risk of major bleeding.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">&gt;10%: Hematologic: &amp; oncologic: Hemorrhage (major: 1% to 11%; minor: 3% to 14%; transfusion required: 2% to 13%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (≤7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (1% to 3%; includes acute profound thrombocytopenia, immune-mediated thrombocytopenia)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing and/or case reports: Anaphylaxis, cerebrovascular accident, gastrointestinal hemorrhage, intracranial hemorrhage, pulmonary hemorrhage</p></div>
<div class="block coi drugH1Div" id="F166039"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to eptifibatide or any component of the formulation; active abnormal bleeding within the previous 30 days or a history of bleeding diathesis; history of stroke within 30 days or a history of hemorrhagic stroke; severe hypertension (systolic blood pressure &gt;200 mm Hg or diastolic blood pressure &gt;110 mm Hg) not adequately controlled on antihypertensive therapy; major surgery within the preceding 6 weeks; current or planned administration of another parenteral GP IIb/IIIa inhibitor; dependency on hemodialysis</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): PT &gt;1.2 times control or INR ≥2.0; known history of intracranial disease (eg, neoplasm, arteriovenous malformation, aneurysm); severe renal impairment (CrCl &lt;30 mL/minute); thrombocytopenia (&lt;100,000 cells/mm<sup>3</sup>); clinically significant liver disease</p></div>
<div class="block war drugH1Div" id="F166022"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bleeding: The most common complication is bleeding, including retroperitoneal, pulmonary, and spontaneous GI and/or GU bleeding; monitor closely for bleeding, especially the arterial access site for the cardiac catheterization. Risk factors for bleeding include older age, a history of bleeding disorders, and concomitant use of drugs that increase the risk of bleeding (thrombolytics, oral anticoagulants, NSAIDs, and/or P2Y12 inhibitors). Patients &lt;70 kg may be at greater risk for major and minor bleeding. Minimize invasive procedures, including arterial and venous punctures, IM injections, and the use of urinary catheters, nasotracheal intubation and nasogastric tubes.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Hypersensitivity reactions have occurred, including anaphylaxis and urticaria.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombocytopenia: Acute, profound thrombocytopenia (immune-mediated and nonimmune mediated) has occurred and may occur within 24 hours of initiation (Cheema 2006; Coons 2005; Nagge 2003; Rezkalla 2003; Salengro 2003). Platelet counts should recover rapidly (within 1-5 days) after discontinuation. Use with extreme caution in patients with platelet counts &lt;100,000/mm<sup>3</sup> (contraindicated in the Canadian labeling). If platelet count decreases to &lt;100,000/mm<sup>3</sup> during therapy, discontinue eptifibatide and heparin if administered concurrently. Specific management guidelines for GP IIb/IIIa induced thrombocytopenia have been published (Huxtable 2006; Llevadot 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal dysfunction (estimated CrCl &lt;50 mL/minute, using Cockcroft-Gault equation); dosage adjustment required. Use is contraindicated in patients dependent upon hemodialysis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Sheath removal: Prior to pulling the sheath after percutaneous coronary intervention (PCI), heparin should be discontinued for 3 to 4 hours and ACT should be &lt;180 seconds or aPTT &lt;50 seconds. Of note, full dose anticoagulation is no longer used after successful PCI procedures. Use standard compression techniques after sheath removal. Monitor the site closely afterwards for further bleeding.</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgery: Discontinue ≥4 hours prior to coronary artery bypass graft surgery (ACC/AHA [Lawton 2022]).</p></div>
<div class="block foc drugH1Div" id="F166033"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Integrilin: 75 mg/100 mL (100 mL [DSC]); 20 mg/10 mL (10 mL [DSC]); 200 mg/100 mL (100 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 75 mg/100 mL (100 mL); 20 mg/10 mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 75 mg/100 mL (100 mL); 20 mg/10 mL (10 mL); 200 mg/100 mL (100 mL)</p></div>
<div class="block geq drugH1Div" id="F166018"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323131"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Eptifibatide Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/10 mL (per mL): $3.60 - $18.78</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg/100 mL (per mL): $1.08 - $5.88</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/100 mL (per mL): $4.80 - $16.24</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866759"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Integrilin: 75 mg/100 mL ([DSC]); 20 mg/10 mL ([DSC])</p></div>
<div class="block adm drugH1Div" id="F166036"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Bolus dose should be withdrawn from the 10 mL vial into a syringe and administered by IV push. Begin continuous infusion (using an IV infusion pump) immediately following bolus administration, administered undiluted directly from the 100 mL vial. The 100 mL vial should be spiked with a vented infusion set.</p></div>
<div class="block use drugH1Div" id="F166034"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Percutaneous coronary intervention: </b>Treatment of patients undergoing percutaneous coronary intervention, including those undergoing intracoronary stenting.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-ST elevation acute coronary syndromes:</b> Treatment of patients with unstable angina or non–ST-segment elevation myocardial infarction, primarily for patients undergoing percutaneous coronary intervention.</p></div>
<div class="block off-label drugH1Div" id="F25483821"><span class="drugH1">Use: Off-Label: Adult</span><p>ST-elevation myocardial infarction</p></div>
<div class="block mst drugH1Div" id="F5174530"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error. </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299277"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F166027"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Agents with Antiplatelet Properties may enhance the antiplatelet effect of Abrocitinib.  Management: Do not use antiplatelet drugs with abrocitinib during the first 3 months of abrocitinib therapy. The abrocitinib prescribing information lists this combination as contraindicated. This does not apply to low dose aspirin (81 mg/day or less).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F166041"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Information related to eptifibatide use in pregnancy is limited (Al-Aqeedi 2008; Bauer 2012; Serna Candel 2019). Myocardial infarction is a medical emergency; maternal treatment should not be withheld because of fears of teratogenicity.</p></div>
<div class="block brc drugH1Div" id="F20617111"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if eptifibatide is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">If present in breast milk, eptifibatide is expected to be destroyed in the infant GI tract and not be orally absorbed via breastfeeding.</p></div>
<div class="block mop drugH1Div" id="F166031"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Coagulation parameters, signs/symptoms of excessive bleeding. Laboratory tests at baseline and monitoring during therapy: hematocrit and hemoglobin, serum creatinine, PT/aPTT (maintain aPTT between 50-70 seconds unless PCI is to be performed), and ACT with PCI (maintain ACT between 200-300 seconds during PCI). Platelet count recommended at 2-4 hours after initiation, and at 24 hours or prior to discharge, whichever is first.</p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;">Assess sheath insertion site and distal pulses of affected leg every 15 minutes for the first hour and then every 1 hour for the next 6 hours. Arterial access site care is important to prevent bleeding. Care should be taken when attempting vascular access that only the anterior wall of the femoral artery is punctured, avoiding a Seldinger (through and through) technique for obtaining sheath access. Femoral vein sheath placement should be avoided unless needed. While the vascular sheath is in place, patients should be maintained on complete bedrest with the head of the bed at a 30° angle and the affected limb restrained in a straight position. </p>
<p style="text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;">Observe patient for mental status changes, hemorrhage, assess nose and mouth mucous membranes, puncture sites for oozing, ecchymosis and hematoma formation, and examine urine, stool and emesis for presence of occult or frank blood; gentle care should be provided when removing dressings.</p></div>
<div class="block pha drugH1Div" id="F166021"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Eptifibatide is a cyclic heptapeptide which blocks the platelet glycoprotein IIb/IIIa receptor, the binding site for fibrinogen, von Willebrand factor, and other ligands. Inhibition of binding at this final common receptor reversibly blocks platelet aggregation and prevents thrombosis.</p></div>
<div class="block phk drugH1Div" id="F166038"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Immediate after initial bolus (&gt;80% inhibition of ADP-induced aggregation achieved 5 minutes after bolus dose); maximal effect achieved within 1 hour (Gilchrist, 2001; Tardiff, 2001) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Platelet function restored ~4 to 8 hours following discontinuation (Tardiff, 2001)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~25% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: ~2.5 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Primarily urine (as eptifibatide and metabolites)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Clearance: Total body: ~55 mL/kg/hour; Renal: ~50% of total body clearance in healthy subjects</p></div>
<div class="block phksp drugH1Div" id="F51154047"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance reduced approximately 50% and steady-state plasma levels are approximately doubled in patients with moderate to severe renal function impairment (CrCl less than 50 mL/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Higher plasma levels and lower total body clearance.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F166042"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatid accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Integril</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Han an</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatid accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Intergrilin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ebatid</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Clotide | Eptiba | Eptifab | Fleta Bolus | Integrilin | Intiflo | Unigrilin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Eptifab | Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Integrilin | Mylan eptifibatide</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Integrilin | Koromax</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatid accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Eptifibatide accord | Integrilin</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Integrilin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-20670756">
<a name="20670756"></a>Akerblom A, James SK, Koutouzis M, et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry). <i>J Am Coll Cardiol</i>. 2010;56(6):470-475.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/20670756/pubmed" id="20670756" target="_blank">20670756</a>]</span>
<span class="doi">10.1016/j.jacc.2009.10.093</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18460716">
<a name="18460716"></a>Al-Aqeedi RF, Al-Nabti AD. Drug-eluting stent implantation for acute myocardial infarction during pregnancy with use of glycoprotein IIb/IIIa inhibitor, aspirin and clopidogrel. <i>J Invasive Cardiol</i>. 2008;20(5):E146-E149.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/18460716/pubmed" id="18460716" target="_blank">18460716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10351964">
<a name="10351964"></a>Antman EM, Giugliano RP, Gibson CM, et al, “Abciximab Facilitates the Rate and Extent of Thrombolysis: Results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. The TIMI 14 Investigators,” <i>Circulation</i>, 1999, 99(21):2720-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10351964/pubmed" id="10351964" target="_blank">10351964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22584549">
<a name="22584549"></a>Bauer ME, Bauer ST, Rabbani AB, Mhyre JM. Peripartum management of dual antiplatelet therapy and neuraxial labor analgesia after bare metal stent insertion for acute myocardial infarction. <i>Anesth Analg</i>. 2012;115(3):613-615. doi:10.1213/ANE.0b013e31825ab374<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/22584549/pubmed" id="22584549" target="_blank">22584549</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brener.1">
<a name="Brener.1"></a>Brener SJ, Barr LA, Burchenal JE, et al, “Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction,” ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators, <i>Circulation</i>, 1998, 98(8):734-41.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16483348">
<a name="16483348"></a>Cheema AA, Teklinski AH, Maria V, et al, “Recurrent Acute Profound Thrombocytopenia Related to Readministration of Eptifibatide,” <i>J Interv Cardiol</i>, 2006, 19(1):99-103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/16483348/pubmed" id="16483348" target="_blank">16483348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644467">
<a name="15644467"></a>Coons JC, Barcelona RA, Freedy T, et al, “Eptifibatide-Associated Acute, Profound Thrombocytopenia,” <i>Ann Pharmacother</i>, 2005, 39(2):368-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/15644467/pubmed" id="15644467" target="_blank">15644467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Athenex.1">
<a name="Athenex.1"></a>Eptifibatide injection [prescribing information]. Schaumburg, IL: Athenex; June 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23098967">
<a name="23098967"></a>Ferraris VA, Saha SP, Oestreich JH, et al, “2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,” <i>Ann Thorac Surg</i>, 2012, 94(5):1761-81.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/23098967/pubmed" id="23098967" target="_blank">23098967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26714677">
<a name="26714677"></a>Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care.</i> 2016;24(1):6-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/26714677/pubmed" id="26714677" target="_blank">26714677</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19264239">
<a name="19264239"></a>Fung AY, Saw J, Starovoytov A, et al, “Abbreviated Infusion of Eptifibatide After Successful Coronary Intervention: The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) Randomized Trial,” <i>J Am Coll Cardiol</i>, 2009, 53(10):837-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/19264239/pubmed" id="19264239" target="_blank">19264239</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11468201">
<a name="11468201"></a>Gilchrist IC, O’Shea JC, Kosoglou T, et al. Pharmacodynamics and pharmacokinetics of higher-dose, double-bolus eptifibatide in percutaneous coronary intervention. <i>Circulation</i>. 2001;104(4):406-411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/11468201/pubmed" id="11468201" target="_blank">11468201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19332455">
<a name="19332455"></a>Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. <i>N Engl J Med</i>, 2009, 360(21):2176-90. doi:10.1056/NEJMoa0901316<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/19332455/pubmed" id="19332455" target="_blank">19332455</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10341274">
<a name="10341274"></a>Hamm CW, Heeschen C, Goldmann B, et al, “Benefit of Abciximab in Patients With Refractory Unstable Angina in Relation to Serum Troponin T Levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators,” <i>N Engl J Med</i>, 1999, 340(21):1623-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10341274/pubmed" id="10341274" target="_blank">10341274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16442410">
<a name="16442410"></a>Huxtable LM, Tafreshi MJ, and Rakkar AN, “Frequency and Management of Thrombocytopenia With the Glycoprotein IIb/IIIa Receptor Antagonists,” <i>Am J Cardiol</i>, 2006, 97(3):426-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/16442410/pubmed" id="16442410" target="_blank">16442410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9705684">
<a name="9705684"></a>“Inhibition of Platelet Glycoprotein IIb/IIIa With Eptifibatide in Patients With Acute Coronary Syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy,” <i>N Engl J Med</i>, 1998, 339(7):436-43.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9705684/pubmed" id="9705684" target="_blank">9705684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merck.1">
<a name="Merck.1"></a>Integrilin (eptifibatide) [prescribing information]. Whitehouse Station, NJ: Merck Sharp &amp; Dohme Corp; March 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Merck.2">
<a name="Merck.2"></a>Integrilin (eptifibatide) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; February 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10468074">
<a name="10468074"></a>Kereiakes DJ, Broderick TM, Roth EM, et al, “Time Course, Magnitude, and Consistency of Platelet Inhibition by Abciximab, Tirofiban, or Eptifibatide in Patients With Unstable Angina Pectoris Undergoing Percutaneous Coronary Intervention,” <i>Am J Cardiol</i>, 1999, 84(4):391-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10468074/pubmed" id="10468074" target="_blank">10468074</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34895950">
<a name="34895950"></a>Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. <i>J Am Coll Cardiol</i>. 2022;79(2):e21-e129. doi:10.1016/j.jacc.2021.09.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/34895950/pubmed" id="34895950" target="_blank">34895950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9207636">
<a name="9207636"></a>Lincoff AM, Califf RM, Anderson KM, et al, “Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications,” <i>J Am Coll Cardiol</i>, 1997, 30(1):149-56.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9207636/pubmed" id="9207636" target="_blank">9207636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10423466">
<a name="10423466"></a>Lincoff AM, Califf RM, Moliterno DJ, et al, “Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators,” <i>N Engl J Med</i>, 1999, 341(5):319-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10423466/pubmed" id="10423466" target="_blank">10423466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10208997">
<a name="10208997"></a>Lincoff AM, Tcheng JE, Califf RM, et al, “Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab: One-Year Outcome in the EPILOG Trial. Evaluation in PTCA to Improve Long-Term Outcome With Abciximab GP IIb/IIIa Blockade,” <i>Circulation</i>, 1999, 99(15):1951-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10208997/pubmed" id="10208997" target="_blank">10208997</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10613999">
<a name="10613999"></a>Llevadot J, Coulter SA, and Giugliano RP, "A Practical Approach to the Diagnosis and Management of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Receptor Inhibitors,” <i>J Thromb Thrombolysis</i>, 2000, 9(2):175-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10613999/pubmed" id="10613999" target="_blank">10613999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10318656">
<a name="10318656"></a>Mahaffey KW, Harrington RA, Simoons ML, et al, “Stroke in Patients With Acute Coronary Syndromes: Incidence and Outcomes in the Platelet Glycoprotein IIb/IIIa in Unstable Angina. Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. The PURSUIT Investigators,” <i>Circulation</i>, 1999, 99(18):2371-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10318656/pubmed" id="10318656" target="_blank">10318656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9626829">
<a name="9626829"></a>Mandak JS, Blankenship JC, Gardner LH, et al, “Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis,” <i>J Am Coll Cardiol</i>, 1998, 31(7):1518-24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9626829/pubmed" id="9626829" target="_blank">9626829</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10359733">
<a name="10359733"></a>McClure MW, Berkowitz SD, Sparapani R, et al, “Clinical Significance of Thrombocytopenia During a Non-ST-Elevation Acute Coronary Syndrome. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Experience,” <i>Circulation</i>, 1999, 99(22):2892-900.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10359733/pubmed" id="10359733" target="_blank">10359733</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12627937">
<a name="12627937"></a>Nagge J, Jackevicius C, Dzavik V, et al, “Acute Profound Thrombocytopenia Associated With Eptifibatide Therapy,” <i>Pharmacotherapy</i>, 2003, 23(3):374-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/12627937/pubmed" id="12627937" target="_blank">12627937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9164315">
<a name="9164315"></a>“Randomised Placebo-Controlled Trial of Effect of Eptifibatide on Complications of Percutaneous Coronary Intervention: IMPACT-II. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis-II,” <i>Lancet</i>, 1997, 349(9063):1422-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9164315/pubmed" id="9164315" target="_blank">9164315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12508202">
<a name="12508202"></a>Rezkalla SH, Hayes JJ, Curtis BR, et al, “Eptifibatide-Induced Acute Profound Thrombocytopenia Presenting as Refractory Hypotension,” <i>Catheter Cardiovasc Interv</i>, 2003, 58(1):76-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/12508202/pubmed" id="12508202" target="_blank">12508202</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12508201">
<a name="12508201"></a>Salengro E, Mulvihill NT, and Farah B, “Acute Profound Thrombocytopenia After Use of Eptifibatide for Coronary Stenting,” <i>Catheter Cardiovasc Interv</i>, 2003, 58(1):73-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/12508201/pubmed" id="12508201" target="_blank">12508201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31903097">
<a name="31903097"></a>Serna Candel C, Hellstern V, Beitlich T, Aguilar Pérez M, Bäzner H, Henkes H. Management of a decompensated acute-on-chronic intracranial venous sinus thrombosis. <i>Ther Adv Neurol Disord</i>. 2019;12:1756286419895157. doi:10.1177/1756286419895157<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/31903097/pubmed" id="31903097" target="_blank">31903097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17299194">
<a name="17299194"></a>Stone GW, Bertrand ME, Moses JW, et al; ACUITY Investigators. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. <i>JAMA</i>. 2007;297(6):591-602. doi: 10.1001/jama.297.6.591<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/17299194/pubmed" id="17299194" target="_blank">17299194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17124018">
<a name="17124018"></a>Stone GW, McLaurin BT, Cox DA, et al; ACUITY Investigators. Bivalirudin for patients with acute coronary syndromes. <i>N Engl J Med</i>. 2006;355(21):2203-2216.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/17124018/pubmed" id="17124018" target="_blank">17124018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18499566">
<a name="18499566"></a>Stone GW, Witzenbichler B, Guagliumi G, et al; HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. <i>N Engl J Med</i>. 2008;358(21):2218-2230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/18499566/pubmed" id="18499566" target="_blank">18499566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9935014">
<a name="9935014"></a>Tardiff BE, Califf RM, Tcheng JE, et al, “Clinical Outcomes After Detection of Elevated Cardiac Enzymes in Patients Undergoing Percutaneous Intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II,” <i>J Am Coll Cardiol</i>, 1999, 33(1):88-96.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9935014/pubmed" id="9935014" target="_blank">9935014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11468200">
<a name="11468200"></a>Tardiff BE, Jennings LK, Harrington RA, et al; PERIGEE Investigators. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT, <i>Circulation</i>. 2001;104(4):399-405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/11468200/pubmed" id="11468200" target="_blank">11468200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9256222">
<a name="9256222"></a>Topol EJ, Ferguson JJ, Weisman HF, et al, “Long-Term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin Beta<sub>3</sub> Blockade With Percutaneous Coronary Intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication,” <i>JAMA</i>, 1997, 278(6):479-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/9256222/pubmed" id="9256222" target="_blank">9256222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10334418">
<a name="10334418"></a>van den Merkhof LF, Zijlstra F, Olsson H, et al, “Abciximab in the Treatment of Acute Myocardial Infarction Eligible for Primary Percutaneous Transluminal Coronary Angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) Pilot Study,” <i>J Am Coll Cardiol</i>, 1999, 33(6):1528-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/10334418/pubmed" id="10334418" target="_blank">10334418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20670755">
<a name="20670755"></a>Zeymer U, Margenet A, Haude M, et al. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial. <i>J Am Coll Cardiol</i>. 2010;56(6):463-469.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/eptifibatide-drug-information/abstract-text/20670755/pubmed" id="20670755" target="_blank">20670755</a>]</span>
<span class="doi">10.1016/j.jacc.2009.08.093</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8918 Version 310.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
